#ES­MO22: De­ci­phera pins its come­back hopes on im­proved TGCT da­ta

PARIS — Last fall De­ci­phera suf­fered through a dis­as­trous set­back $DCPH with its lead drug, Qin­lock, which had been ap­proved as a fourth-line ther­a­py for gas­troin­testi­nal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER